and hepatic steatosis or osteoscarcoma in clinical population, and (iii) the associations between the different CTRP3 isoforms (CTRP3A and CTRP3B) and multimeric structures in clinical populations, (iv) the potential use of CTRP3 as an inhibitor of inflammation, and (v) whether the putative receptors, LAMP1 and LIMPII are directly responsible for the intracellular effects of CTRP3 or at as coreceptors for a yet unidentified protein. Finally, the gender-specific regulation of CTRP3 needs to be explored in more detail (splice variants and multimeric structures) especially in regards to the association between CTRP3 and human diseases such as non-alcoholic fatty liver disease, T2D, and metabolic syndrome.
